Editorial of utility of the Global Lung Function Initiative (GLI) for ILD

Tomoo Kishaba
DOI: https://doi.org/10.1136/thorax-2024-222356
2024-10-17
Thorax
Abstract:Interstitial lung disease (ILD) is a heterogeneous parenchymal disorder.1 2 Patients with ILD often present with non-specific symptoms such as a non-productive cough and exertional dyspnoea. The differential diagnosis for ILD is broad and includes conditions such as connective tissue disease (CTD), hypersensitivity pneumonitis, drug-associated ILD and granulomatous diseases. Furthermore, the initial management depends on factors such as antigen exposure, causative drugs, inflammation and fibrosis. Accurate diagnosis requires a detailed medical history, chest high-resolution CT (HRCT) and pathology.3 4 From a physiological perspective, ILD manifests as a restrictive disorder with reduced diffusion capacity of the lungs for carbon monoxide (DLco).5–7 Many clinical trials on ILD have used forced vital capacity (FVC) as a surrogate marker for mortality.8 9 Additionally, trends in FVC and DLco have been shown to be useful predictors...
respiratory system
What problem does this paper attempt to address?